TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20410913
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 2 or 3 g day(‐1) plus oral corticosteroids
Study: 20410913
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus oral corticosteroids
Study: 15823285
Drug: orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: orlistat 120 mg plus a moderate-fat meal (MFO)
Study: 15823285
Drug: orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: orlistat 120 mg plus a high-fat meal (HFO)
Study: 12433452
Drug: Salbutamol dry
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol dry powder formulations (50 microg to 400 microg)
Study: 10526025
Drug: Single-stage laparoscopic
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-stage laparoscopic management (Group B): Single-stage laparoscopic treatment.
Study: 8719512
Drug: DTaP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP vaccine (acellular pertussis vaccine containing pertussis toxoid, filamentous hemagglutinin, and pertactin)
Study: 8719512
Drug: DTP-Connaught (whole-cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP-Connaught (whole-cell pertussis vaccine)
Study: 8719512
Drug: DTP-Lederle (whole-cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP-Lederle (whole-cell pertussis vaccine)
Study: 6117309
Drug: Prizidilol hydrochloride
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prizidilol hydrochloride 400 mg
Study: 6117309
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg + Hydralazine 25 mg or 50 mg
Study: 30973344
Drug: Internet-delivered computerized
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered computerized cognitive behavioral therapy (ICBT) plus usual care (UC)
Study: 22126282
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) plus systemic amoxicillin (500 mg) and metronidazole (400 mg) 3 times a day for 14 days
Study: 20881664
Drug: Aerosolized nebulization
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized nebulization of amphotericin B lipid complex at 1 mg/kg every 24 hr for 4 days
Study: 18981770
Drug: Lopinavir/ritonavir [400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir [400/100 mg twice a day (LPV/r)]
Study: 18981770
Drug: Tipranavir/ritonavir [500/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipranavir/ritonavir [500/200 mg twice a day (TPV/r200)]
Study: 18981770
Drug: Tipranavir/ritonavir [500/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipranavir/ritonavir [500/100 mg twice a day (TPV/r100)]
Study: 15799981
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nurse intervention and consumer-directed voucher
Study: 12750967
Drug: Prompt L‐Pop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt L‐Pop + experimental flowable composite
Study: 10364993
Drug: Propofol 20
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 20 mg i.v. every 30 s to a maximum of 5 mg kg‐1
Study: 10364993
Drug: Thiopental 25
Normalized name: thiopental 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 25 mg i.v. every 30 s
Study: 8896392
Drug: PEG‐rHuMGDF at
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐rHuMGDF at doses of 0.3 and 1.0 microgram/kg/d
Study: 2071885
Drug: Amitriptyline (clinically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (clinically effective doses)
Study: 2071885
Drug: Tranylcypromine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranylcypromine (single treatment)
Study: 2071885
Drug: Amitriptyline and
Normalized name: amitriptyline and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline and Tranylcypromine (combination treatment)
Study: 30691396
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated varicella-zoster vaccine
Study: 24667460
Drug: Nasal glucagon-like
Normalized name: Glucagon-like peptide II (2-glycine) (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal glucagon-like peptide-1 (GLP-1) 1.2 mg administered before every meal for 2 weeks
Study: 22971530
Drug: Bisphosphonates (clodronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonates (clodronate therapy group)
Study: 22971530
Drug: Simple chemotherapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple chemotherapy (control group)
Study: 15057674
Drug: Humalog Mix50
Normalized name: Insulin lispro 100 [iU] in 1 mL SUBCUTANEOUS INJECTION, SUSPENSION [Humalog Mix50/50]
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Humalog Mix50 injected three times daily
Study: 15057674
Drug: Premixed human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premixed human insulin 30/70 injected twice daily
Study: 8623866
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (1080 mg icosapentaenoic acid, 720 mg docosahexaenoic acid, and 1.5 mg vitamin E) daily for 2 months
Study: 1535329
Drug: Didemnin B
Normalized name: Dehydrodidemnin B
DrugBank: Plitidepsin (DB04977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didemnin B at 2.6 mg/m2 iv every 28 days
Study: 1535329
Drug: Didemnin B
Normalized name: Dehydrodidemnin B
DrugBank: Plitidepsin (DB04977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didemnin B at 5.6 mg/m2 iv every 28 days
Study: 1535329
Drug: Trimetrexate at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetrexate at 12 mg/m2/day iv for 5 days, repeated every 21 days
Study: 6419679
Drug: Oral lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lysine hydrochloride therapy (400 mg, three times a day)
Study: 16181527
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of DU20, DU26, and HT7
Study: 10782483
Drug: Propolis ointment
Normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis ointment applied four times daily
Study: 10782483
Drug: Acyclovir ointment
Normalized name: Acyclovir Ointment
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir ointment applied four times daily
Study: 10782483
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment applied four times daily
Study: 10782483
Drug: Propolis ointment
Normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis ointment
Study: 4074444
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg AQ‐A 39 intravenously
Study: 22819549
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g of glucose
Study: 29190155
Drug: PC-18 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC-18 at 37.5 mg twice daily
Study: 29190155
Drug: PC-18 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC-18 at 7.5 mg twice daily
Study: 29190155
Drug: PC-18 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC-18 at 12.5 mg twice daily
Study: 20645521
Drug: Azelaic acid
Normalized name: Azelaic Acid
DrugBank: Azelaic acid (DB00548)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azelaic acid gel 15% plus doxycycline 40 mg once daily
Study: 20645521
Drug: Metronidazole gel
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole gel 1% plus doxycycline 40 mg once daily
Study: 19137909
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of famotidine with calcium carbonate and magnesium hydroxide
Study: 19137909
Drug: Common formulation
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common formulation of famotidine
Study: 8339853
Drug: Sulodexide administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulodexide administration during hyperglycaemia
Study: 11791960
Drug: Myrrh at
Normalized name: Myrrh
DrugBank: Myrrh (DB11605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myrrh at a dose of 10 mg/kg of body weight/day for three days
Study: 11791960
Drug: Myrrh at
Normalized name: Myrrh
DrugBank: Myrrh (DB11605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myrrh at a dose of 10 mg/kg of body weight/day for six days (re-treatment)
Study: 11791960
Drug: Biopsy specimens
Normalized name: SPECIMEN CONTAINER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biopsy specimens six months after treatment
Study: 29319209
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with fluoroquinolone prophylaxis
Study: 29319209
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy without prophylaxis (DFCI 05-001)
Study: 27093482
Drug: Folic acid-containing
Normalized name: Folic acid-containing product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folic acid-containing supplements
Study: 27093482
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no supplements, no TMs)
Study: 27093482
Drug: Supplement only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement only
Study: 27093482
Drug: TM +
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TM + supplement
Study: 20961243
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (including balloon aortic valvuloplasty)
Study: 7538514
Drug: Controlled-release hydromorphone
Normalized name: hydromorphone Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release hydromorphone (CR)
Study: 7538514
Drug: Immediate-release hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release hydromorphone (IR)
Study: 1689988
Drug: KRN 8601
Normalized name: KRN-5500
DrugBank: KRN-5500 (DB15215)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRN 8601 (rhG-CSF) at a dose of 75 micrograms/body administered subcutaneously for 14 days after the second cycle of chemotherapy
Study: 456734
Drug: Trimebutine (Mebutin),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimebutine (Mebutin), 200 mg three times daily for 4 weeks
Study: 27547895
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention consisting of a review lecture, electronic information card, and monthly individual physician feedback via email.
Study: 22507979
Drug: Mipomersen 200
Normalized name: mipomersen 200 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipomersen 200 mg weekly subcutaneous injection
Study: 16054553
Drug: Nut diet
Normalized name: Coconut diethanolamide
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nut diet (30 g/d nuts)
Study: 8991314
Drug: Therapists classified
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapists classified as more effective based on patient outcomes in active treatment.
Study: 1460207
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (Atrovent nasal spray)
Study: 30278407
Drug: P(v-a)CO2/C(a-v)O2-targeted therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: P(v-a)CO2/C(a-v)O2-targeted therapy
Study: 30278407
Drug: ScvO2-targeted therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ScvO2-targeted therapy
Study: 16239885
Drug: 23.4% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23.4% sodium chloride solution
Study: 11929393
Drug: ABT-229 (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-229 (1.25 mg, 2.5 mg, 5 mg, 10 mg b.d.)
Study: 8062495
Drug: Combination product
Normalized name: Drug-device combination product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination product of trimethoprim (15 mg/kg/day) and sulfamethoxazole (75 mg/kg/day)
Study: 8062495
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who discontinued therapy due to toxicity
Study: 3232130
Drug: Ticlopidine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (250 mg b.i.d. for 21 months)
Study: 27977819
Drug: Deep chamfer
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep chamfer preparation
Study: 26445857
Drug: Feather edge
Normalized name: Gallus gallus feather
DrugBank: Gallus gallus feather (DB10420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feather edge preparation
Study: 24756814
Drug: Adjuvant external
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant external beam radiation therapy (EBRT)
Study: 21850496
Drug: Blood orange
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL SPRAY [All Clean Premium Hand Sanitizer Blood Orange]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood orange juice (1 L/day for 4 weeks)
Study: 21850496
Drug: Blond orange
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blond orange juice (1 L/day for 4 weeks)
Study: 20021703
Drug: Multispecies probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multispecies probiotic (5 g, twice daily for 2 weeks)
Study: 11872201
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5 mg daily) and placebo
Study: 11872201
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate (66 mg daily) and placebo
Study: 11872201
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate (66 mg daily) and folic acid (5 mg daily)
Study: 9788828
Drug: Enalapril (E)
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril (E) 20 mg/d
Study: 7340881
Drug: Frusemide (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide (0.25 mg/kg)
Study: 7340881
Drug: Piretanide (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide (0.1 mg/kg)
Study: 7340881
Drug: Gentamicin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin alone (1 mg/kg)
Study: 30848803
Drug: Systolic blood
Normalized name: Bystolic
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systolic blood pressure target of less than 120 mm Hg (intervention treatment)
Study: 28017248
Drug: Apraclonidine 0.5%–1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apraclonidine 0.5%–1% solution, 2 drops to each eye
Study: 17562231
Drug: Vinorelbine (25-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine (25-30 mg/m² on days 1 and 8 every 3 weeks)
Study: 11219633
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol maleate, administered bilaterally for 3 weeks
Study: 8054251
Drug: Ketoprofen (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (3 mg kg‐1 day‐1)
Study: 8054251
Drug: Flurbiprofen (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (3 mg kg‐1 day‐1)
Study: 8054251
Drug: Piroxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (20 mg day‐1)
Study: 8054251
Drug: Non-NSAID control
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-NSAID control (paracetamol/acetaminophen)
Study: 3133575
Drug: Systemic natural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic natural alpha interferon (IFN) therapy
Study: 26122012
Drug: Cord blood
Normalized name: CORD BLOOD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cord blood 25(OH)D 25‐50 nmol/L at delivery
Study: 26122012
Drug: Cord blood
Normalized name: CORD BLOOD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cord blood 25(OH)D >50 nmol/L at delivery
Study: 26122012
Drug: Cord blood
Normalized name: CORD BLOOD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cord blood 25(OH)D <25 nmol/L at delivery
Study: 21930067
Drug: Rehabilitation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation group (supervised physical therapy training for 6 weeks + unsupervised maintenance program for 6 weeks)
Study: 19371843
Drug: Lidocaine 10
Normalized name: lidocaine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 10 mg/kg
Study: 19371843
Drug: Lidocaine 20
Normalized name: lidocaine 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 20 mg/kg
Study: 19371843
Drug: Lidocaine 30
Normalized name: lidocaine 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 30 mg/kg
Study: 19371843
Drug: Postoperative morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative morphine equivalence requirements
Study: 16416228
Drug: Fructose-sorbitol mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose-sorbitol mixture (25 g fructose and 5 g sorbitol)
Study: 10583701
Drug: Generic digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic digoxin preparation
Study: 8975569
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amitriptyline, propranolol, and phenazepam for causalgic form
Study: 8975569
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of carbamazepine, propranolol, and phenazepam for neuralgic form
Study: 8975569
Drug: Tizanidine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine monotherapy for spastic form
Study: 6348635
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin E administered early (<12 hours of age)
Study: 6348635
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin E administered after 39 hours of age (mean age 167.5 hours)
Study: 6348635
Drug: Early parenteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early parenteral and oral vitamin E
Study: 26335078
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate 50 mg/kg
Study: 30355096
Drug: 4-factor prothrombin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-factor prothrombin complex concentrate and vitamin K infusion followed by intravenous thrombolysis (IVT)
Study: 21093036
Drug: Control (previous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (previous treatment alone)
Study: 15672113
Drug: Yogurt (1100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogurt (1100 mg Ca/day)
Study: 15672113
Drug: Control (400‐500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (400‐500 mg Ca/day)
Study: 12804845
Drug: INFLUSOME-VAC (IL-2-supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: INFLUSOME-VAC (IL-2-supplemented trivalent liposomal influenza vaccine)
Study: 12804845
Drug: Standard trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard trivalent split virion vaccine (control)
Study: 12804845
Drug: INFLUSOME-VAC and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: INFLUSOME-VAC and Standard vaccine
Study: 20398248
Drug: Cranberry powder
Normalized name: Cranberry powder/extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry powder standardized for proanthocyanidin content (72 mg of PAC per day)
Study: 18590519
Drug: Gradual 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual 1 strategy (olanzapine at 50% entry dose for 1 week after risperidone initiation)
Study: 18590519
Drug: Gradual 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual 2 strategy (olanzapine at 100% entry dose for 1 week, then at 50% in the second week)
Study: 15971073
Drug: Sodium ferric
Normalized name: Sodium ferric EDTA
DrugBank: Sodium feredetate (DB13381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium ferric gluconate complex (SFGC) therapy at 1.5 mg kg(‐1)
Study: 15971073
Drug: Sodium ferric
Normalized name: Sodium ferric EDTA
DrugBank: Sodium feredetate (DB13381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium ferric gluconate complex (SFGC) therapy at 3.0 mg kg(‐1)
Study: 15971073
Drug: Sodium ferric
Normalized name: Sodium ferric EDTA
DrugBank: Sodium feredetate (DB13381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium ferric gluconate complex (SFGC) therapy (both doses)
Study: 12452021
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose chemotherapy combined with total body irradiation (TBI) or total lymph node irradiation (TLI)/subtotal lymph node irradiation (STLI)
Study: 12452021
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose chemotherapy alone
Study: 12452021
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (HDT combined with ASCT)
Study: 8461508
Drug: Nitroglycerin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (1 microgram/kg per min, low dose)
Study: 8461508
Drug: Nitroglycerin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (2 micrograms/kg per min, high dose)
Study: 3954933
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of amoxycillin as a single i.v. infusion
Study: 3954933
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of ampicillin as a single i.v. infusion